Gilead commends South Africa’s launch of long-acting HIV prevention drug
Gilead Sciences (NASDAQ:GILD) has formally recognized the South African government’s leadership in accelerating the nationwide rollout of lenacapavir, a long-acting injectable medication designed for HIV pre-exposure prophylaxis (PrEP).


_1415148_640x360_2502635587876-640x360.webp&w=3840&q=75)
_1415125_640x360_2502635075512-640x360.webp&w=3840&q=75)
_1415123_640x360_2502630979873-640x360.webp&w=3840&q=75)
_1415112_640x360_2502632003926-640x360.webp&w=3840&q=75)
_1415109_640x360_2502630979859-640x360.webp&w=3840&q=75)
_1415082_640x360_2502604867685-640x360.webp&w=3840&q=75)
_1415080_640x360_2502617155528-640x360.webp&w=3840&q=75)


